1) ~(131)I
131I
1.
In this paper,method and principle of calibrating γdetecting efficiency of~(131)I charcoal cartridge sampler based on~(133)Ba standard source instead of~(131)I standard source are introduced.
介绍了一种基于133B a标准源代替131I标准源刻度N aI(T l)闪烁体探测器对131I取样滤盒的γ总探测效率的原理和方法。
2.
To investigate the relationship between prognosis of Graves disease(GD) treated with ~(131)I and IL-2,IL-10 and TNF-α,the levels of IL-2,IL-10,TNF-α,T3,T4,FT3,FT4 and s-TSH in serum of 158 patients with GD were measured before first ~(131)I treatment and after five months.
探讨Graves病131I治疗后的转归与细胞因子IL-2、IL-10、TNF-α之间的关系。
3.
Objective To evaluate the role of amiodarone combined with ~(131)I in Graves disease complicated with atrial fibrillation.
目的研究胺碘酮联合131I治疗伴发房颤的G raves病的疗效。
2) Iodine-131
131I
1.
Methods Iodine-131 labeled anti-CD20McAb by iodogen method.
目的探讨131I-anti-CD20McAb经瘤内注射后在荷人Burkitt’s淋巴瘤细胞系Raji细胞移植瘤裸鼠体内的放射免疫显像。
2.
Methods:Iodine-131 labeled anti-CD20 McAb by iodogen method.
目的:探讨131I-anti-CD20 McAb经瘤内注射后在荷人Burkitts淋巴瘤细胞系Raji细胞移植瘤裸鼠体内的动态分布。
3) ~(131)I-MPPI
131I-MPPI
1.
The synthesis and biological evaluation of serotonin(5HT_(1A)) imaging agent _4-iodo-N-_1-piperazinyl]ethyl-N-2-pridinyl-benzami-de(~(131)I-MPPI)were reported.
为了找到适合123I标记的5-羟色胺(5-HT1A)受体显像剂,合成了4-三正丁基锡-N-[2-[1-(2-甲氧基苯基)]-1-哌嗪基]乙基-N-2-吡啶基-苯甲酰胺(MPPBu3Sn,标记前体),并采用双氧水标记法进行131I标记,得到标记物131I-MPPI,标记率大于90%,放化纯大于99%。
4) ~(131)I-IMPY
131I-IMPY
1.
The synthesis and biodistribution of β-amyloid plaques imaging agent _2-(4′-dimethylaminophenyl)-6-iodoimidazo\ pyridine(~(131)I-IMPY) is reported.
为了找到合适的123I标记的脑内β淀粉样蛋白(Aβ)斑块的显像剂,根据文献资料,合成了2-(4′-二甲基氨基苯基)-6-三正丁基锡咪唑并[1,2-α]吡啶(IMPY),并采用双氧水标记法进行了131I标记,得到标记物131I-IMPY,放射化学纯度大于95%。
5) 131 I-IBZM
131I-IBZM
1.
Objective To evaluate the usefulress of SPECT with 131 I-IBZM in imaging of D 2 Dopamine receptors in patients with Parkinson s disease(PD).
目的 探讨131I-IBZM脑多巴胺D2 受体SPECT显像在帕金森病中的临床应用价值。
6) 131I therapy
131I治疗
1.
Objective To study the value of TSAb detection for hypothyroidism after in 131I therapy on hyperthyreosis.
目的探讨131I治疗甲亢患者后发生甲状腺功能减退症与TSAb、MCA的关系。
2.
Objective To determine the relationgship between the serum levels of Tg and TgAb by reviewing the results of patients with differentiated thyroid cancer(DTC) before every 131I therapy.
方法:DTC患者141例,首次131I治疗前检查128人次,重复治疗前检查共计120人次,按Tg水平分为5组,比较各组间TgAb阳性率。
3.
To investigate dynamic change of serum receptor and antibody of thyrotrophic antibody(TRAb) and its prognosis value after a one-off successful therapy on Graves disease with 131I,257 Graves disease patients were treated with one dose of 131I therapy.
分析Graves病131I治疗一次性成功后,患者血清促甲状腺激素受体抗体(TRAb)的动态变化规律及其预后价值。
补充资料：iodohippurate sodium [131I]
分子式：
CAS号：
性质：又称邻碘[131I]马尿酸钠。本品由邻碘马尿酸与碘[131I]化钠为原料制得。静注本品后，立即随血流进入肾脏；其中20％由肾小球滤过，80％由肾小管分泌，碘[131I]从血流经肾尿路的全过程。用于肾功能检查、肾显像以及泌尿道通畅情况观察。制剂为注射剂。注意：孕妇、哺乳妇慎用；有过敏反应的可能；铅器存放。副作用有恶心、呕吐、皮肤发红、痒及昏厥的病例报告。
CAS号：
性质：又称邻碘[131I]马尿酸钠。本品由邻碘马尿酸与碘[131I]化钠为原料制得。静注本品后，立即随血流进入肾脏；其中20％由肾小球滤过，80％由肾小管分泌，碘[131I]从血流经肾尿路的全过程。用于肾功能检查、肾显像以及泌尿道通畅情况观察。制剂为注射剂。注意：孕妇、哺乳妇慎用；有过敏反应的可能；铅器存放。副作用有恶心、呕吐、皮肤发红、痒及昏厥的病例报告。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条